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Available online 17 February 2012Variability in pre-analytical blood sampling and handling can significantly impact results
obtained in quantitative immunoassays. Understanding the impact of these variables is critical
for accurate quantification and validation of biomarker measurements. Particularly, in the de-
sign and execution of large clinical trials, even small differences in sample processing and han-
dling can have dramatic effects in analytical reliability, results interpretation, trial management
and outcome. The effects of two common blood sampling methods (serum vs. plasma) and two
widely-used serum handling methods (on the clot with ambient temperature shipping, “tradi-
tional”, vs. centrifuged with cold chain shipping, “protocol”) on protein and autoantibody con-
centrations were examined. Matched serum and plasma samples were collected from 32
rheumatoid arthritis (RA) patients representing a wide range of disease activity status. Addi-
tionally, a set of matched serum samples with two sample handling methods was collected.
One tube was processed per manufacturer's instructions and shipped overnight on cold packs
(protocol). The matched tube, without prior centrifugation, was simultaneously shipped over-
night at ambient temperatures (traditional). Upon delivery, the traditional tube was centri-
fuged. All samples were subsequently aliquoted and frozen prior to analysis of protein and
autoantibody biomarkers. Median correlation between paired serum and plasma across all
autoantibody assays was 0.99 (0.98–1.00) with a median % difference of −3.3 (−7.5 to 6.0).
In contrast, observed protein biomarker concentrations were significantly affected by sample
types, with median correlation of 0.99 (0.33–1.00) and a median % difference of −10 (−55
to 23). When the two serum collection/handling methods were compared, the median correla-
tion between paired samples for autoantibodies was 0.99 (0.91–1.00) with a median difference
of 4%. In contrast, significant increases were observed in protein biomarker concentrations
among certain biomarkers in samples processed with the ‘traditional’ method. Autoantibody
quantification appears robust to both sample type (plasma vs. serum) and pre-analytical sam-
ple collection/handlingmethods (protocol vs. traditional). In contrast, for non-antibody proteinKeywords:
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73X. Zhao et al. / Journal of Immunological Methods 378 (2012) 72–80biomarker concentrations, sample type had a significant impact; plasma samples generally ex-
hibit decreased protein biomarker concentrations relative to serum. Similarly, sample handling
significantly impacted the variability of protein biomarker concentrations. When biomarker
concentrations are combined algorithmically into a single test score such as a multi-
biomarker disease activity test for rheumatoid arthritis (MBDA), changes in protein biomarker
concentrations may result in a bias of the score. These results illustrate the importance of char-
acterizing pre-analytical methodology, sample type, sample processing and handling proce-
dures for clinical testing in order to ensure test accuracy.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license. 1. Introduction
Mutliplexed immunoassays that provide multiple, parallel
protein measurements on the same specimen have become
popular tools in biomarker discovery research and the
measurement of protein biomarkers in clinical trials. By mea-
suring several proteins from a single sample, multiplexed im-
munoassays offer the advantages of specimen conservation,
high throughput analysis, and efficiency in terms of time
and cost. Given the complexity ofmultiplexed immunoassays,
rigorous investigation of pre-analytical requirements in addi-
tion to extensive validation of analytical performance is nec-
essary to ensure the reliability and consistency of assay
results (Ellington et al., 2009, 2010). An understanding of
the pre-analytical requirements of multiplexed immunoas-
says is particularly important since studies have shown that
the majority of variations and errors in protein biomarker
measurements occur in the pre-analytical phase prior to spec-
imen analysis (Rai and Vitzthum, 2006). Indeed, studies have
shown that even small differences in pre-analytical variables,
such as the processing or handling of a specimen, can dramat-
ically affect the analytical reliability and reproducibility of
multiplex immunoassays (Tuck et al., 2009).
The importance of pre-analytical variables has been rec-
ognized in the context of clinical trials. Multiplexed immuno-
assays for measurement of protein biomarkers have the
potential to improve the value of clinical trials and can be in-
tegral to the design of a trial, and the development of well-
defined protocols for sample collection and processing has
been recommended in order to minimize the risk of inadver-
tently introducing subtle differences in sample handling that
may affect study results (Dancey et al., 2010; Sturgeon et al.,
2010). Given their relatively high cost, clinical trials aim to
obtain as much information as possible. However, trials
often involve more than one center and more than one spec-
imen type may be collected (biological fluids, tissue, etc.),
and hence a thorough understanding and characterization
of the pre-analytical variables that impact assay performance
are critical. These variables include the method of sample col-
lection, the type of anticoagulants or preservatives that are
used, the procedure used to process the sample, the time be-
tween collection and assay, and the storage conditions used
during this interval (Gerszten et al., 2008). Ideally, these
pre-analytical variables should be evaluated for each individ-
ual assay included in the multiplex assay (Wener, 2011).
Recently, multiplexed immunoassays have been intro-
duced for the diagnosis and classification of rheumatoid ar-
thritis (RA) (Hueber et al., 2005; Curtis et al., 2010; Chandra
et al., 2011). RA is an inflammatory joint disease that involves
complex interactions between multiple proteins in a numberof tissues, including bone, cartilage and synovium (Graudal et
al., 1998). The molecular pathophysiology of RA remains
unclear, and patients with RA vary considerably in the course
of disease and response to treatment (Scott and Steer, 2007).
It has been shown that regular quantitative assessment of RA
disease activity, termed tight control, is key to improving pa-
tient outcomes (Grigor et al., 2004; Goekoop-Ruiterman et al.,
2005). Although several biomarkers that are predictive of RA
disease activity have been identified, no single biomarker ad-
equately reflects disease activity or response to RA therapy
(van der Pouw Kraan et al., 2003; Hueber et al., 2007; Rioja
et al., 2008; Chandra et al., 2011). Hence, the use of multi-
plexed immunoassays to simultaneously measure multiple
biomarkers may provide a more comprehensive, objective
measure of disease activity that could be used as a comple-
ment to other clinical measures of RA to improve patient
outcomes.
The multi-biomarker disease activity (MBDA) test is a mul-
tiplexed immunoassay available through the CLIA-certified
laboratory at Crescendo Bioscience (Vectra™ DA; Crescendo
Bioscience™, South San Francisco, CA) that employs an algo-
rithm based on the measurement of 12 protein biomarkers to
provide a measure of disease activity for patients with RA
(Curtis et al., 2010). As part of a comprehensive program to
assess the performance of the MBDA test in clinical practice,
other studies have evaluated the criterion and discriminant va-
lidity of the MBDA score (Curtis et al., 2010) as well as the an-
alytical validity of the MBDA test with regards to precision,
dynamic range, cross-reactivity, and effect of interfering sub-
stances (Eastman et al., 2010). In the present study, we exam-
ined the effect of pre-analytical variables related to the
collecting, processing and handling of blood samples on the
performance of the MBDA test and each of the protein bio-
marker immunoassays that comprise the MBDA test. Here, we
report on the measurement of the protein biomarkers and
MBDA score in serum versus plasma as well as in serum sam-
ples processed by two different methods. For comparison, we
also evaluated the effects of these pre-analytical variables on
the measurement of autoantibodies typically found in RA pa-
tients using custom immunoassays developed on the
Meso Scale Discovery (MSD) platform. The data indicate that
blood collection, processing, and handling methods had a sig-
nificant impact on some non-antibody protein biomarkermea-
surements, whereas autoantibody measurements appeared
relatively robust to these pre-analytical variables. Changes in
the protein biomarker concentrations from pre-analytical
sample handling introduced a bias in the MBDA score. The re-
sults of this study illustrate the importance of characterizing
pre-analytical variability to ensure the accuracy of protein bio-
marker tests, and confirm that standardized serum processing
Table 2
Sourcesa of capture antibody, detection antibody and analyte standards.
Biomarker Capture antibody Detection antibody Analyte standard
VCAM-1 R&D Systems R&D Systems R&D Systems
EGF R&D Systems R&D Systems Peprotech
VEGF-A Peprotech R&D Systems Peprotech
IL-6 R&D Systems R&D Systems Peprotech
TNF-R1 R&D Systems R&D Systems Peprotech
MMP-1 R&D Systems R&D Systems R&D Systems
MMP-3 R&D Systems R&D Systems R&D Systems
YKL-40 Quidel Quidel Peprotech
Leptin R&D Systems Hytest Peprotech
Resistin Antigenix America R&D Systems Peprotech
SAA Anogen Anogen Peprotech
CRP Hytest Hytest Peprotech
a Source locations: Anogen (Mississauga, Ontario, Canada); Antigenix
America (Huntington Station, NY); Hytest (Turku, Finland); Peprotech (Rocky
Hill, NJ); Quidel (San Diego, CA); R&D Systems (Minneapolis, MN).
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to ensure the reliability of results obtained in clinical trials.
2. Materials and methods
2.1. Materials
2.1.1. Autoantibody biomarkers
The peptides derived from potential RA autoantigens used
in this study are listed in Table 1. All peptides were synthe-
sized by Biomer Technology (Pleasanton, CA) with a terminal
biotin. Labeled secondary antibody against human IgG was
from Meso Scale Discovery (MSD, Gaithersburg, MD).
2.1.2. Protein biomarkers
Sources for the capture antibodies, detection antibodies,
and analyte standards used to measure the 12 protein bio-
markers that comprise the MBDA test are listed in Table 2. All
other reagents, with the exception of wash buffer components,
were from MSD.
2.1.3. Multiplex standards for MBDA test
Prediluted multiplexed calibrator sets were prepared for
each panel. Each standard curve consisted of 8 points spanning
the full range of the assay, including an assay blank. Prediluted
standards were prepared with recombinant proteins spiked
into the appropriate sample diluent containing the equivalent
serum concentration that is present in diluted samples. Predi-
luted standards were aliquoted into single-use vials and stored
at−80 °C.
2.1.4. Assay quality controls for MBDA test
Prediluted, multiplexed quality control (QC) run control
sets were used to monitor the execution of each assay run. If
the observed biomarker concentrations of any QC run control
fell outside of expected ranges, all samples on the failed assay
plate were repeated.
Serum process controls were used to monitor the entire
assay process, including sample dilution, at both the biomarker
level and the score level. If any process control failed theMBDA
score specifications, all samples on the plates which contained
the failed process control were repeated.
For patient samples, the percent coefficient of variation (%
CV) of the signals between the duplicate wells was calculated
for each marker. If the % CV was above the biomarker specific
acceptability limit (typically 20%), the concentration reported
for that sample was deemed unreliable and was retested.Table 1
Peptides used in the study.
Peptide ID Protein source Sequence
cApoE Apolipo E A[CIT]LKSWFEPLVE
cBig Biglycan EDLL[Cit]YSKLY[Cit]
cH2B Histone 2B IMNSFVNDIFE[Cit]IA
cClu Clusterin HFS[Cit]ASSIIDELFQ
cFibA1 Fibrinogen A THSTK[CIT]GHAKS[C
cFil Filaggrin TIHAHPGS[CIT][CIT]
H2B Histone 2B PEPVKSAPVPKKGSK
cFibA2 Fibrinogen A NTKESSSHHPGIAEFP2.1.5. Instrumentation
Microplates are read on the SECTOR Imager 6000 reader
(MSD, Gaithersburg, MD), which uses an ultra-low noise
charge-coupled device (CCD) camera with a custom-designed
telecentric lenses to detect light emitted at ~620 nm upon
electrochemical stimulation. Plate images are obtained in six
sectors and data is subsequently acquisitioned into MSD Dis-
covery Workbench Software.
2.2. Methods
2.2.1. Sample collection protocol: serum vs. plasma
Paired serum and plasma samples were collected from RA
subjects who fulfilled the American College of Rheumatology
(ACR) 1987 criteria (Arnett et al., 1988). All samples were col-
lected under Investigational Review Board approved protocols
with informed consent. To collect samples, 32 individuals
with RA had matched serum and plasma samples drawn with
SerumSeparator Transport (SST™) Tubes and EDTAVacutainer
tubes from Becton Dickinson (BD, Franklin Lakes, NJ), respec-
tively, from the same needle stick. Both the serum and plasma
tubes were processed per manufacturer's instructions, aliquots
prepared, frozen and subsequently tested in the MBDA protein
biomarker and autoantibody biomarker assays.
2.2.2. Serum sample collection protocol: ‘protocol’ vs. ‘traditional’
To evaluate serum collection and handling variables,
serum samples were collected from 10 individuals who
were diagnosed with RA based on ACR 1987 criteria (Arnett
et al., 1988). All samples were collected under Investigational
Review Board approved protocols with informed consent.Citrullinated Cyclized
DMQ[CIT]QWAG + +
LGLGHNQI[Cit] + −
GEAS[Cit]L + +
D[Cit]FFT[Cit] + +
IT]PV[CIT]GIHTS + +
GGRHGYHH + +
KAIN − +
S[cit]GK + −
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tubes from each individual was incubated at ambient tem-
perature for 30–45 min and then centrifuged for 10 min at a
1000 to 1300 RCF (g) per manufacturer's instructions. This
was followed by overnight shipment in a temperature con-
trolled (2–8 °C) package (“protocol”). A matched tube from
each individual was simultaneously shipped overnight at
ambient temperature while remaining on the clot (e.g. not
centrifuged; “traditional”). Upon arrival, the traditional tube
was centrifuged and all samples were aliquoted and frozen
for analysis in the MBDA lower case protein biomarker and
autoantibody biomarker immunoassays. The 10 matched
sets of processed serum were run on two duplicate plates
for each multiplexed panel (panels A, B, and C). Due to limit-
ed amount of samples available, only 7 matched sets were
analyzed for autoantibody experiments.
2.2.3. Autoantibody biomarker measurements
The autoantibody biomarkers were evaluated with cus-
tom assays using the MSD platform. Briefly, eight peptides
(Table 1) were immobilized onto streptavidin MSD plates.
All incubations were applied with continuous shaking at
750 rpm and plates were washed 3 times between incuba-
tions with wash buffer (phosphate buffered saline+0.05%
Tween-20, PBST). After blocking with blocker A from MSD
for 1 h, the plates were probed with 50 μL of samples that
were diluted 1/50 in sample diluents supplemented with
10% fetal calf serum (FCS) and incubated for 90 min. SULFO-
TAG conjugated secondary antibody against human immuno-
globulin G (IgG, MSD, Gaithersburg, MD) was diluted 1/5000
and used to quantitatively measure the presence of each
autoantibody. Electrochemiluminescence signal was quanti-
fied on the SECTOR Imager 6000 reader immediately after
150 μL of MSD Read Buffer T (containing surfactants and tri-
propylamine as a coreactant for light generation) was loaded
in each well. Samples collected under different conditions
were run in duplicate on one plate and raw signals were
used for data analysis.
2.2.4. Protein biomarker measurements
The 12 protein biomarkers that constitute the MBDA test
were measured using analyte-specific capture and detection
antibodies. Briefly, multi-spot 96-well plates were coated
with analyte-specific capture antibodies on three panels:
panel A includes epidermal growth factor (EGF), interleukin-6
(IL-6), leptin, and vascular endothelial growth factor (VEGF-
A); panel B includes C-reactive protein (CRP), serum amyloid
A (SAA), and vascular cell adhesion protein 1 (VCAM-1); and
panel C includes matrix metalloproteinase-1 (MMP-1), MMP-
3, resistin, tumor necrosis factor receptor 1 (TNF-R1), and
cartilage glycoprotein-39 (gp-39, also known as YKL-40). Dilu-
tions for panels A, B and C were 1/2, 1/1000 and 1/20, respec-
tively. Fifty microliters (for panels A and C) and 25 μL (for
panel B) of standard, blank, control, or sample were added to
the appropriate well in the 96-well plate. The plates were incu-
bated for 120 min with continuous shaking at 750 rpm
and then washed 3 times in PBST wash buffer. Twenty-five
microliters of prediluted blends of SULFO-TAG conjugated
detection antibodieswas added to eachwell. Following incuba-
tion with the detection antibody blend for 60 min, plates
were washed again, and upon adding 150 μL of read buffer,the electrochemiluminescence signal was quantified as in
Section 2.2.3. MSD Discovery Workbench calculates the four-
parameter logistic regression curve fits (Findlay and Dillard,
2007) for each standard curve and determines concentrations
for all samples. The concentration of the samples was used for
further comparison of results obtained with different sample
collecting/handling processes.
2.3. Calculations
TheMBDA algorithmwas developed in a separate series of
studies and clinically validated in an independent cohort
(Curtis et al., 2010) using the DAS28-CRP as a gold standard
(Prevoo et al., 1995; Inoue et al., 2007). Derivation and clinical
validation of this algorithm are reported elsewhere (Curtis et
al., 2010). The MBDA algorithm was developed by analyzing
biomarker assays performed on samples from several obser-
vational studies (Verstappen et al., 2007; Karlson et al., 2008).
PTJC ¼ Prediction of Tender Joint Count ¼−26:72
þ3:243  YKL  40½ 1=10−11:97  EGF½ 1=10
þ15:72  IL  6½ 1=10 þ 0:4594  Leptin½ 1=10
þ3:881  SAA½ 1=10 þ 0:7388  TNF RI½ 1=10
−0:2557  VCAM 1½ 1=10 þ 0:7003  VEGF A½ 1=10
PSJC ¼ Prediction of Swollen Joint Count ¼−26:63
þ3:232  YKL  40½ 1=10−11:93  EGF½ 1=10
þ15:67  IL  6½ 1=10 þ 0:4578  Leptin½ 1=10
þ3:868  SAA½ 1=10 þ 0:7363  TNF RI½ 1=10
−0:2548  VCAM 1½ 1=10 þ 0:6979  VEGF A½ 1=10
PPGS ¼ Prediction of Patient Global Score ¼−13:489
þ5:474  IL  6½ 1=10 þ 0:486  SAA½ 1=10
þ2:246  MMP 1½ 1=10 þ 1:684  Leptin½ 1=10
þ4:14  TNF RI½ 1=10 þ 2:292  VEGF A½ 1=10
–1:898  EGF½ 1=10 þ 0:028  MMP 3½ 1=10
–2:892  VCAM 1½ 1=10–0:506  Resistin½ 1=10
MBDA score ¼ round

max

min

:56  sqrt

max PTJC;0ð Þ

þ :28  sqrt

max PSJC;0ð Þ

þ :14  PPGS
þ :36  log CRP=106 þ 1
 
 10:53þ 1;100

;1

All concentration values except that of CRP are X1/10
transformed prior to use in the algorithm.
MBDA algorithm scores are integers from1 to 100, with dis-
ease activity thresholds designed to be equivalent to thresholds
from DAS28CRP:
• MBDA algorithm scores ≤29 are considered low disease
activity.
• MBDA algorithm scores of 30 to ≤44 are considered mod-
erate disease activity.
• MBDA algorithm scores >44 are considered high disease
activity.
Table 3
Correlation and % change of marker measurements on paired serum/plasma
samples.
Slopea rb Median % changec
Autoantibody biomarkers
cApoE 0.91 0.98 −8
cBig 1.02 0.98 −4
cH2B 1.00 0.99 6
cClu 0.89 1.00 −3
cFibA1 1.07 0.98 −3
cFil 0.97 0.99 2
H2B 1.05 0.99 −5
cFibA2 0.91 0.99 −5
Protein biomarkers
VCAM-1 0.75 0.97 −19
EGF 0.21 0.33 −51
VEGF-A 0.34 0.87 −55
IL-6 0.93 1.00 −6
TNF-R1 1.03 0.99 −7
MMP-1 1.28 0.74 23
MMP-3 0.90 1.00 −9
YKL-40 1.13 0.99 −7
Leptin 1.21 0.99 6
Resistin 0.84 0.91 −18
SAA 1.02 1.00 −12
CRP 0.88 1.00 −12
MBDA 0.78 0.93 3
a Slope of the linear regression line.
b Correlation coefficient.
c Median % change=(plasma−serum)/serum.
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3.1. Comparison of plasma vs. serum samples
3.1.1. Autoantibody biomarker measurements in plasma and
serum samples
All autoantibody assays exhibited less than 10% difference
(median difference) between the two sample types (Table 3),
well within the Food and Drug Administration suggested
specification at ±15% for accuracy (FDA, 2001). All analyses
for autoantibodies were calculated on raw signals in antibody
biomarker measurements. An additional more stringent anal-
ysis compared the correlation coefficient and slope of linear
regression. In comparison of plasma and serummatched sam-
ple sets, the correlation was 0.99 (0.98 to 1.00) with a slope of
approximately 1.00, indicating little or no difference in quan-
titation of autoantibody signals in serum vs. plasma samples.
3.1.2. Protein biomarker concentration comparisons between
plasma and serum samples
For protein biomarkers of matched plasma and serum
samples, only 67% of the biomarkers were highly correlated
achieving correlation coefficients of 0.95 (range 0.33–1.00)
(Table 3). The protein concentrations had a systematic shift
with the slope of most markers being less than 1.00, indicat-
ing serum concentrations were measured higher for most
biomarkers. The plasma EGF concentrations were not corre-
lated with matched serum EGF concentrations (correlation
coefficient of 0.33).
As shown in Fig. 1A, 5 out of 12 protein biomarkers
(VCAM-1, EGF, VEGF-A, MMP1 and resistin) had shifts >15%
in the median % difference in concentration across the 32patient samples. Aside from leptin andMMP-1, median protein
concentrations in plasma were lower than those in serum.
While the median change for MMP-1 showed significantly
greater concentrations in plasma over serum (Fig. 1A), the indi-
vidual subjects in this study provided mixed results, with 12
subjects' plasma showing lower MMP-1 concentrations and
20 subjects with greater MMP-1 concentrations.
3.2. Impact of serum sample handling: traditional vs. protocol
3.2.1. Serum sample handling for autoantibody assays
Autoantibody measurements between traditional and
protocol samples showed median differences of generally
less than 15% (Table 4). The autoantibody levels between
these two sample handling methods were highly correlated,
with a median correlation coefficient of 0.99 (0.91–1.00).
Slopes of their linear regression curve across the 32 subjects
were spread between 0.7 and 1.4.
3.2.2. Serum sample handling for protein biomarker
measurements
When correlations of protein concentrations frommatched
sets of samples across the 32 subjects were calculated between
traditional and protocol handlingmethods, only 7 of the 12 bio-
markers achieved correlation coefficients≥0.95with a range of
0.05 to 1.00 (Table 4).
As shown in Fig. 1B, significant differences in biomarker
concentrations, (>±15%median percent difference) between
the two sample handling methods were seen in 67% (8/12) of
the individual biomarkers measured. Of the markers with sig-
nificant differences in the traditional samples, 7 biomarkers
increased, while only leptin decreased. The EGF and IL-6
serum concentrations in samples handledwith the traditional
method increased as much as 40-fold, while VEGF-A and
resistin concentrations also increased 2 to 4-fold.
3.3. MBDA and pre-analytical variables
The MBDA scores were evaluated across different pre-
analytical variables. In Fig. 2A, a bias was observed when
the difference of MBDA scores between plasma and serum
was plotted against the MBDA scores of the serum samples.
Samples with low serumMBDA scores had artificially inflated
scores when plasma was used as a sample. While changes in
the concentration of several biomarkers were observed in
this subset of samples, e.g., EGF, VEGF-A, resistin, the largest
and most consistent change associated with the elevated
MBDA score was reduced concentrations of EGF which has a
negative coefficient in the algorithm. In Fig. 2B, a similar
bias was observed when the difference of MBDA scores be-
tween the traditional vs. protocol serum sample handling
methods was evaluated relative to the MBDA score for the
protocol method. Again, samples with low “protocol” MBDA
scores were artificially inflated by the traditional method,
but this time primarily as a result of the elevated concentra-
tion of IL-6. In both comparisons, samples with artificially de-
flated scores were observed at high MBDA scores. While
changes in several of the biomarkers were observed in the
samples with the deflated MBDA scores, elevated EGF con-
centrations were consistently observed.
ABiomarkers
B
Biomarkers
Fig. 1. Changes of biomarker concentrations in paired samples. A, Plasma versus serum samples. Percent changes were determined by using the difference of bio-
marker concentrations between plasma and serum samples divided by biomarker concentrations in serum samples. B, Traditional versus protocol sample han-
dling. Percent change is the difference of biomarker concentration between the traditional and protocol methods relative to the concentration from the
protocol method. Median and inter-quartile ranges are presented.
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This study investigated two types of pre-analytical vari-
ables that occur prior to the point of actual sample analysis:
blood sampling methods (serum vs. plasma) and serum col-
lection/handling methods (traditional vs. protocol). Although
serum and plasma are both routinely collected samples and
the composition is considered similar, this is the first study
to the authors' knowledge where quantitative measurements
of 12 proteins in a multiplexed platform and eight autoanti-
bodies from matched samples are compared in a systematic
way in rheumatoid arthritis subjects. We observed that ef-
fects of pre-analytical variables were remarkably different
on protein biomarkers vs. antibody biomarkers. It is critical
to collect samples under well-defined protocols for both bio-
marker discovery and validation studies, especially because
even within a panel of multiplexed biomarker assays, differ-
ent biomarkers were affected very differently by these pre-
analytical variables.Previous studies comparing plasma and serum have
shown that the measurable levels of analytes may vary be-
tween the 2 sample types (Miles et al., 2004). Quantifications
with two common RA autoantibody assays, anti-cyclic citrul-
linated peptides (CCP) and rheumatoid factor (RF) have
been demonstrated equivalent with either serum or plasma
(Rantapaa-Dahlqvist et al., 2003).When sample handling var-
iables, such as sample type (e.g., serum vs. plasma), room
temperature storage, heat treatment, hemolysis, and repeti-
tive freeze–thaw cycles, were evaluated on the performance
of immunoassay detection of antibodies against Erysipelothrix
rhusiopathiae (Neumann and Bonistalli, 2009), no significant
impact was found suggesting that immunoglobulin G anti-
body was stable in cases of common sample mishandling
events. Autoantibodies are human immunoglobulins against
an individual's own proteins and should present similar char-
acteristics to antibodies against bacteria. In fact, our results
confirmed that antibodies appear to be stable biomarkers
that were not largely affected by pre-analytical variables.
Table 4
Correlation of marker measurements on paired traditional/protocol samples.
Slopea rb Median % changec
Autoantibody biomarkers
cApoE 0.80 0.99 −16
cBig 0.70 0.91 −4
cH2B 0.72 1.00 10
cClu 1.37 0.98 −6
cFibA1 1.07 0.99 2
cFil 0.76 0.99 −24
H2B 0.89 0.95 5
cFibA2 0.90 0.96 −4
Protein biomarkers
VCAM-1 0.99 0.98 −1
EGF 1.70 0.72 416
VEGF-A 1.10 0.90 112
IL-6 0.27 0.05 329
TNF-R1 1.13 0.99 16
MMP-1 0.92 0.98 17
MMP-3 0.92 0.97 1
YKL-40 0.97 0.87 83
Leptin 0.71 0.98 −29
Resistin 2.69 0.89 235
SAA 0.91 0.94 −5
CRP 0.98 1.00 1
MBDA 0.42 0.65 1
a Slope of the linear regression line.
b Correlation coefficient.
c Median % change=(traditional−protocol) /protocol.
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Fig. 2. Correlation of MBDA scores and changes in MBDA scores. A, Plasma
versus serum samples. Changes were determined by using the difference
of MBDA scores between plasma and serum samples. B, Traditional versus
protocol samples. Changes were determined by using the difference of
MBDA scores between plasma and serum samples.
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ples is largely within +/−15%. The impact of blood sampling
(serum vs. plasma) was minimal for autoantibody quantifica-
tion with correlation coefficients near 1.0.
For the non-antibody protein biomarker assays, the differ-
ence between plasma and serum concentrations was depen-
dent on individual biological characteristics of the proteins.
Concentrations of some protein biomarkers were lower in
plasma than in serum, e.g., VEGF-A, EGF, VCAM-1 and resistin,
while other protein biomarkers exhibited no significant
change. For CRP, we have observed a correlation of 1.00 be-
tween plasma and serum samples, with median difference of
12%. This result agreed with previous studies when CRP was
measured in matched plasma and serum samples in protein
biomarker measurements (Miles et al., 2004). For MMP-1,
however, we observed a wide range of concentration changes
between RA subjects, with 60% demonstrating increased
concentrations in plasma and 40% of RA subjects showing de-
creased concentrations. The CVs of all duplicate measure-
ments were less than 10% (data not shown), so that assay
variability is not likely contributing to the diverse results.
Protein biomarker concentrations are also greatly affected
by post-collection sample handling methods. One can sur-
mise that this is a result of blood cell lysis when samples
had prolonged (>12 h) contact with blood cells at room
temperature (traditional conditions). Not surprisingly, this
sample handling method appeared to predominantly affect
blood cell secreted proteins, such as EGF, VEGF-A, IL-6, YKL-
40 and resistin. Among them, both EGF and IL-6 concentra-
tions had a median increase of 3–4 fold, respectively. On the
other hand, some proteins are not known to be secreted by
blood cells. For example, VCAM-1 is expressed in endothelial
cells (Osborn et al., 1989), both SAA (Uhlar and Whitehead,1999) and CRP (Pepys and Hirschfield, 2003) are produced
predominantly by the liver. All three proteins remained sta-
ble to the traditional sample handling.
As the pre-analytical sample handling has an impact on
non-antibody protein concentrations, it would stand to rea-
son that it may also impact the results of a multi-biomarker
disease activity algorithm. The MBDA scores from samples
that were obtained by different pre-analytical sample types
and sample handling variables were evaluated. The use of
plasma, as compared to serum, significantly impacted a large
number of subjects' MBDA score, with changes from +18 to
−8 MBDA units (Fig. 2A). The MBDA score obtained from
serum handled by the traditional method also resulted in sig-
nificant changes,−8 to +24MBDA units (Fig. 2B), relative to
the protocol method. With both pre-analytical variables, the
magnitude of the change of MBDA scores was inversely corre-
lated with the MBDA scores measured with serum samples.
79X. Zhao et al. / Journal of Immunological Methods 378 (2012) 72–805. Conclusions
Autoantibody biomarker measurements appear robust to
blood collection and handlingmethods. In contrast, blood col-
lection, processing and handling methods had a significant
impact on measurable serum protein concentrations. Plasma
samples generally exhibited decreased levels for the protein
biomarkers assayed. The results of this study illustrate the im-
portance of characterizing pre-analytical variability to ensure
test accuracy for development, validation, and clinical testing
with biomarker assays. This is especially critical when these
assays are integrated in large clinical trials, where using stan-
dardized serum processing and handling procedures would
be an essential part of the study design, directly affecting re-
sults interpretation and next phase of trials.
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